$192.42
4.74[2.53%]
At close: Jun 6
$192.42
0[0.00%]
After Hours: 4:00PM EDT
Insulet
(NASDAQ:PODD)Latest News for Insulet Stock (NASDAQ:PODD)
Insulet Stock (NASDAQ: PODD)
Categories: All
Thursday, May 30, 2024
Sunday, May 19, 2024
Tuesday, May 14, 2024
- Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems MarketVandana Singh
- Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday?Piero Cingari
- zer0es.tv Previews Video On X Saying "Soren Aandahl of @blueorcainvest is out today with their latest idea: short Insulet Corporation ( $PODD) and long its upstart Korean competitor EOFlow because, undisclosed to investors, last week the Federal Court of Appeals killed a preliminary injunction that protected Insulet's key monopoly against competition from EOFlow."Benzinga Newsdesk
Monday, May 13, 2024
Friday, May 10, 2024
- Insulet shares are trading lower after the company reported Q1 financial results.Benzinga Newsdesk
- Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $234Benzinga Newsdesk
- Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? (CORRECTED)Piero Cingari
- Raymond James Maintains Outperform on Insulet, Lowers Price Target to $213Benzinga Newsdesk
- Jefferies Maintains Buy on Insulet, Raises Price Target to $260Benzinga Newsdesk
Thursday, May 09, 2024
Tuesday, May 07, 2024
Wednesday, March 20, 2024
Friday, March 08, 2024
Tuesday, March 05, 2024
Thursday, February 29, 2024
Monday, February 26, 2024
- On Thursday February 22, Insulet Gave Q1 2024 Revenue Growth Guidance Of 17%-20%; For FY24, The Company Expects Revenue Growth In The Range Of 12%-17%Benzinga Newsdesk
- Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On MondayAvi Kapoor
- Insulet shares are trading lower after Barclays maintained an Equal-Weight rating on the stock and lowered its price target from $214 to $213.Benzinga Newsdesk
- Barclays Maintains Equal-Weight on Insulet, Lowers Price Target to $213Benzinga Newsdesk
Friday, February 23, 2024
- JP Morgan Maintains Overweight on Insulet, Raises Price Target to $225Benzinga Newsdesk
- Analyst Scoreboard: 5 Ratings For InsuletBenzinga Insights
- Insulet shares are trading lower after the company reported Q4 financial results.Benzinga Newsdesk
- Nasdaq, S&P 500 Set for Mixed Open After Nvidia Euphoria: Analyst Picks Major Market Catalyst This Year If There Are No Rate CutsShanthi Rexaline
Thursday, February 22, 2024
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights
- Insulet shares are trading lower after the company reported Q4 financial results.Benzinga Newsdesk
- Insulet: Q4 Earnings InsightsBenzinga Insights
- Insulet Q4 2023 Adj EPS $1.40 Beats $0.66 Estimate, Sales $509.80M Beat $461.05M EstimateBenzinga Newsdesk
- Nasdaq, S&P 500 Futures Jump As Nvidia Surge Raises 'FOMO' Rally Hopes: Analyst Tells Why Jobs Data Holds Key For MomentumShanthi Rexaline
- Earnings Scheduled For February 22, 2024Benzinga Insights
Thursday, February 08, 2024
Monday, February 05, 2024
Monday, January 22, 2024
Thursday, December 21, 2023
- Insulet shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $180 to $238.Benzinga Newsdesk
- Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For ThursdayAvi Kapoor
- Expert Ratings For InsuletBenzinga Insights
- Baird Upgrades Insulet to Outperform, Raises Price Target to $238Benzinga Newsdesk